GlassScriptPhysician profile
Sandra Talal Nasser
NPI 1184260077
$3,998.39
in general payments reported to CMS, 2019-2025
28 companies · $740 in 2025
The $740 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $730 · 2022: $1,010 · 2023: $859 · 2024: $659 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.09 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $506.39 | 2021-2025 | Evenity, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $447.71 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.65 | 2021-2025 | Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.43 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $284.21 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $226.34 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $223.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $210.12 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $153.62 | 2024-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $113.71 | 2023-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $98.35 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $84.43 | 2022-2023 | Nuplazid |
| Glaxosmithkline, LLC. | $73.58 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $62.47 | 2023-2024 | Watchman Flx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $51.99 | 2024-2025 | Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $51.40 | 2022 | |
| Novartis Pharmaceuticals Corporation | $44.08 | 2022-2023 | |
| Abbvie INC. | $43.38 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $28.97 | 2022-2023 | Austedo Xr |
| Corcept Therapeutics | $24.07 | 2025 | Korlym |
| Alnylam Pharmaceuticals INC. | $22.90 | 2025 | Givlaari |
| Xeris Pharmaceuticals, INC. | $22.85 | 2023 | Gvoke Hypopen |
| Shield Therapeutics INC | $19.92 | 2022 | |
| Dexcom, INC. | $19.50 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $14.54 | 2025 | Flucelvax, Fluad |
| Medicomp INC | $14.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Nasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.